- Home
- CABA vs LEGO Comparison
CABA vs LEGO Comparison
Compare CABA & LEGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CABA | LEGO |
|---|---|---|
| Founded | 2017 | 2025 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Steel/Iron Ore |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 319.6M | 298.2M |
| IPO Year | 2019 | 2026 |
Fundamental Metrics
Financial Performance| Metric | CABA | LEGO |
|---|---|---|
| Price | $3.67 | $9.92 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $14.50 | N/A |
| AVG Volume (30 Days) | ★ 5.1M | 21.9K |
| Earning Date | 05-14-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 10.26 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.26 | $9.84 |
| 52 Week High | $4.23 | $9.92 |
Technical Indicators
Market Signals| Indicator | CABA | LEGO |
|---|---|---|
| Relative Strength Index (RSI) | 55.61 | 59.56 |
| Support Level | $2.11 | $9.90 |
| Resistance Level | $3.73 | $9.92 |
| Average True Range (ATR) | 0.24 | 0.01 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 61.41 | 93.75 |
Price Performance
Historical ComparisonAbout CABA Cabaletta Bio Inc.
Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies and exploring their potential to provide a deep and durable, perhaps curative, treatment for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells, that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies: CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) that have the potential to be applied across a broad range of autoimmune diseases.